Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results.
The company is advancing two late-stage oncology programs: rinzimetostat for prostate cancer, with a phase III trial underway and strong safety differentiation, and enozertinib for lung cancer, targeting brain metastases with upcoming data at ESMO. Both programs address large markets, are well-fund…
The company is advancing two late-stage oncology programs: rinzimetostat for prostate cancer, now in Phase III, and enozertinib for lung cancer, with a key data update expected soon. Differentiation is driven by safety and brain penetrance, with large commercial opportunities and a strong cash runw…
Two late-stage oncology programs are advancing, with rinzimetastat in phase III for prostate cancer and enozertinib targeting lung cancer. Key differentiators include safety and potential resistance advantages, with major data readouts and program updates expected over the next 12—18 months.Based o…